Table 4.

Chemotherapy regimens used in third-line (n=27).

Systemic third-line therapy (n=27)	N (%)	Median number of cycles (range)	ORR [%]	Median PFS [months]	Median OS [months]
Systemic treatment total	17 (63.0%)	2 (1-4)	17.7%	1.3	3.2
ACO	4 (23.5%)	3.5 (2-4)	25%	1.3	7.5
Topotecan	6 (35.3%)	1 (1-2)	0%	1.4	2.5
Cisplatinum-etoposide	1 (5.9%)	2	100%	1.3	2.0
Carboplatinum-etoposide	3 (17.6%)	1 (1-2)	0%	1.3	2.7
ACE	1 (5.9%)	6	100%	7.3	12.3
Dotatoc	2 (11.8%)	1	0%	1.1	2.8
No systemic treatment	10 (37.0%)	-	-	-	1.1

ACO, adriamycin, cyclophosphamide and vincristine; ACE, adriamycin, cyclophosphamide and etoposide; ORR, overall response rate; OS, overall survival; PFS, progression-free survival